APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Reports Mixed Q2 2025 Results with EPS Beat and Revenue Miss

APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) reported its second-quarter 2025 financial results, revealing mixed performance relative to analyst expectations. The biopharmaceutical company posted revenue of $178.49 million, falling short of the consensus estimate of $192.29 million. However, its earnings per share (EPS) of -$0.33 outperformed the anticipated -$0.49, suggesting better-than-expected cost management or operational efficiency.

Key Financial Highlights

• Revenue Miss: Reported sales of $178.49M vs. $192.29M expected, a shortfall of ~7.2%.
• EPS Beat: Loss of $0.33 per share compared to an estimated loss of $0.49, a positive surprise of ~32.7%.
• Pre-Market Reaction: Shares rose ~4.58% in pre-market trading, indicating investor optimism despite the revenue miss.
• Recent Performance: The stock has seen modest gains over the past month (+6.32%) but remains slightly negative over the past two weeks (-3.8%) and week (-0.05%).

Business Developments

The earnings release highlighted regulatory progress, including U.S. FDA approval for EMPAVELI® (pegcetacoplan) for treating C3G and primary IC-MPGN in patients aged 12 and older. This expansion could bolster future revenue streams, though the immediate financial impact was not enough to meet Q2 sales expectations.

Forward-Looking Estimates

Analysts project:

• Q3 2025 Revenue: $262.51M (vs. negligible revenue growth estimate of $0.0046M, suggesting a potential data discrepancy).
• Full-Year 2025 Sales: $843.87M, though revenue estimates appear conflicting (currently showing a negative figure, which may indicate an error in data interpretation).

The market’s positive pre-market reaction suggests investors are focusing on the EPS beat and regulatory milestones rather than the revenue miss. However, the conflicting forward estimates warrant caution until clarified.

For a deeper dive into APELLIS PHARMACEUTICALS INC’s earnings and analyst projections, visit the earnings estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.